大博医疗(002901) - 2021 Q1 - 季度财报

Financial Performance - Revenue for Q1 2021 reached ¥375,030,218.30, an increase of 62.84% compared to ¥230,304,243.38 in the same period last year[7] - Net profit attributable to shareholders was ¥130,569,345.57, up 46.39% from ¥89,190,527.51 year-on-year[7] - Net profit after deducting non-recurring gains and losses was ¥124,391,597.93, representing an 80.43% increase from ¥68,943,151.81 in the previous year[7] - Basic earnings per share increased to ¥0.33, a 50.00% rise from ¥0.22 in the previous year[7] - Operating profit for Q1 2021 was CNY 156,768,803.99, up 48.0% from CNY 106,038,595.61 in Q1 2020[69] - The total comprehensive income for the period was CNY 135,090,185.91, compared to CNY 86,697,207.88 in the previous year, marking an increase of approximately 55.8%[70] Cash Flow - Net cash flow from operating activities was ¥52,724,072.25, a significant improvement of 740.18% compared to a negative cash flow of ¥8,235,865.28 in the same period last year[7] - Cash flow from operating activities generated a net inflow of CNY 52,724,072.25, a turnaround from a net outflow of CNY -8,235,865.28 in the same quarter last year[76] - The total cash inflow from operating activities was 422,781,049.92 CNY, compared to 232,495,229.52 CNY in the previous period, marking an increase of about 81.7%[81] - The company reported a cash and cash equivalents balance of 16,425,530.57 CNY at the end of the period, down from 18,130,857.12 CNY in the previous period, reflecting a decrease of approximately 9.4%[82] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,744,683,289.84, reflecting a 4.06% increase from ¥2,637,596,622.12 at the end of the previous year[7] - Total liabilities decreased slightly to CNY 492,678,974.21 from CNY 503,657,636.55, a reduction of approximately 2.0%[60] - The company's total equity increased to CNY 2,252,004,315.63 from CNY 2,133,938,985.57, reflecting a growth of about 5.5%[61] - Accounts payable rose significantly to CNY 233,992,171.94 from CNY 179,833,146.20, an increase of approximately 30.1%[59] Investments - The company reported a significant increase in investment income, reaching ¥3,338,885.23, up 868.90% from ¥344,607.25, mainly due to increased maturity of structured deposits[28] - The cash outflow for investment reached ¥1,311,095,604.00, a 119.23% increase from ¥598,040,000.00, primarily due to increased purchases of bank financial products[29] - The total committed investment for the trauma spine orthopedic consumables expansion project is CNY 180 million, with an adjusted total investment of CNY 230 million[43] - The cumulative investment for the trauma spine orthopedic consumables expansion project reached CNY 238.27 million, achieving an investment progress of 103.59%[43] Research and Development - Research and development expenses for Q1 2021 were CNY 31,098,383.66, an increase of 26.1% compared to CNY 24,639,137.42 in Q1 2020[68] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[64] Government Subsidies and Other Income - The company received government subsidies totaling ¥4,144,922.30 during the reporting period[8] - Other income decreased by 82.59% to ¥4,144,922.30 from ¥23,806,269.18, primarily due to fewer government subsidies received in the current period[28] Financial Management - The company has engaged in wealth management with a total amount of CNY 51.64 million, with no overdue amounts[49] - The independent directors support the company's foreign exchange hedging activities, which aim to reduce exchange rate fluctuation risks[38] - The company has not made significant changes to its accounting policies regarding derivative investments compared to the previous reporting period[38]